# Combination treatment with acupoint therapy and conventional medication for non-motor symptoms in Parkinson’s disease: a systematic review and meta-analysis

**Authors:** Wenjiao Hu, Hao Zhou, Wenwen Zhu, Songcheng Xie, Yue Zeng, Zhengyan Wang

PMC · DOI: 10.3389/fneur.2025.1381500 · Frontiers in Neurology · 2025-05-22

## TL;DR

This study reviews and analyzes the effectiveness of combining acupoint therapy with conventional medicine for treating non-motor symptoms in Parkinson's disease.

## Contribution

The paper provides the first systematic review and meta-analysis of acupoint therapy for Parkinson’s non-motor symptoms.

## Key findings

- Combining acupoint therapy with conventional medicine improved outcomes like depression and cognitive function in Parkinson’s patients.
- The study found significant heterogeneity due to differences in disease severity and intervention methods.
- Acupoint therapy combined with conventional medicine showed better results than single-therapy approaches in most measures.

## Abstract

Managing Parkinson’s non-motor symptoms (PD-NMS) is challenging. Traditional methods have limited efficacy for NMS. Acupoint therapy offers a safe and personalized option. There has been a growing number of studies on acupoint therapies for PD-NMS. However, a systematic review of their effectiveness and safety is currently not available. Therefore, this study aims to evaluate the effectiveness and safety of acupoint therapy for PD-NMS.

PubMed, Web of Science, Cochrane Library, Embase, China National Knowledge Infrastructure, Wanfang Database, China Science and Technology Journal Database, and Chinese Biomedical Literature Database were searched. Data were analyzed using fixed or random effects models. Randomized controlled trials (RCT) in Chinese and English relating to acupoint therapy for NMS in PD (PD-NMS), individuals diagnosed with PD, primary and secondary outcome measures are HAMD, MMSE, MoCA, PDSS, PSQI were included. Cochrane risk-of-bias tool (ROB 2) for RCT was used. Meta-analyses were performed to calculate the RR and WMD. Subgroup analyses, sensitivity analyses, and funnel plot analyses were conducted.

Forty-two studies (3120 PD-NMS patients) from database establishment to May 2023 were included. According to the ROB 2 evaluation, risks of bias in random sequence generation, missing data and selective reporting were low, moderate in allocation concealment, and high in blinding. Acupoint therapy combined with CM or NDT was more effective than single-therapy in most outcome measures like effective rate, HAMD, MoCA, PDSS and PSQI, but the MMSE difference was non-significant.

Due to the large number of research subjects, differences in the severity of the diseases, and possible variations of the intervention details, there is a certain degree of heterogeneity in the research results. However, acupoint therapy or acupoint therapy combined with CM could be an option for the treatment of PD-NMS in the future.

This review protocol has been registered in PROSPERO (ID: CRD42023426305). https://www.crd.york.ac.uk/PROSPERO/.

## Linked entities

- **Diseases:** Parkinson’s disease (MONDO:0005180)

## Full-text entities

- **Diseases:** Parkinson's non-motor symptoms (MESH:D010302), PD (MESH:D010300), NMS (MESH:D009459)
- **Chemicals:** CM (MESH:D003476), NDT (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12137075/full.md

## Figures

12 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12137075/full.md

## References

100 references — full list in the complete paper: https://tomesphere.com/paper/PMC12137075/full.md

---
Source: https://tomesphere.com/paper/PMC12137075